Dr. Fava obtained his MD from the University of Padova School of Medicine where he completed residency training in endocrinology. He completed residency training in psychiatry at Mass General. He founded and was Director of the hospital’s Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry.

Under Dr. Fava’s direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $95,000,000. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.

Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 800 original articles published in medical journals with international circulation, edited eight books, and published more than 50 chapters and over 600 abstracts.

View Disclosures Here

Dr. Rosenbaum is recognized as one of the world’s foremost authorities on mood and anxiety disorders, with a special emphasis on pharmacotherapy of those conditions. His research contributions include extensive participation in the design and conduct of clinical trials of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.
Dr. Rosenbaum has authored more than 300 original articles and reviews and has published 12 books. He currently serves on 12 editorial boards of professional journals or newsletters. A particular research interest has been ongoing longitudinal studies of children at risk for anxiety disorders and depression, which has sought to understand risk and protective factors for later psychopathology, including early temperamental features, genetic variations and brain imaging differences.
Dr. Rosenbaum’s clinical and consulting practice specializes in treatment resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions.
Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Massachusetts General Hospital, Harvard Medical School.

John A. Fromson, MD

John A. Fromson, MD, is Acting Director of the Massachusetts General Hospital Psychiatry Academy and Director of Professional Development, Department of Psychiatry at Brigham and Women’s Hospital. He is also past President of the Massachusetts Psychiatric Society and Co-editor of the American Society of Addiction Psychiatry (ASAM) Weekly. He is certified by the American Board of Psychiatry and Neurology (ABPN) in psychiatry, child psychiatry, and addiction psychiatry.
His clinical and research activities focus on issues relating to physician and medical student health, professional development, and patient safety. He is a member of the American Psychiatric Association’s (APA) Council on Addiction Psychiatry, past chair of the APA Committee on Physician Health, Illness, and Impairment, and was the founding director and served as president of Physician Health Services, a national model in identifying, monitoring, and guiding the recovery of physicians and medical students with substance use disorders and mental and physical illness. He is also chair of the American Academy of Addiction Psychiatry’s Special Interest Group on Physician Health, and past president of the Federation of State Physician Health Programs. He was elected Class A Trustee of the General Service Board of Alcoholics Anonymous, Inc. (AA).
Dr. Fromson is also past president of the Massachusetts Coalition for the Prevention of Medical Errors. During his term, the Coalition developed two statewide collaborative projects to support hospitals in implementing safe practices in the areas of reconciling medications and communicating critical test results. These were subsequently adopted by the Joint Commission in its National Patient Safety Goals. Three-year funding for these projects was provided by the Agency for Healthcare Research and Quality (AHRQ). He also chaired its Restraint Consensus Group that developed the first statewide best practices for creating restraint-free environments in hospitals, long-term care, and psychiatric facilities.
For his work in the areas of patient safety and physician and medical student health, Dr. Fromson is the recipient of the Massachusetts Psychiatric Society’s Outstanding Psychiatrist Award for Advancement of the Profession. He is a Distinguished Life Fellow of the American Psychiatric Association and of the American Academy of Child and Adolescent Psychiatry. Dr. Fromson is Professor of Clinical Psychiatry at Harvard Medical School, received the Harvard Medical School Class of 2017 Excellence in Clinical Instruction Award, and twice received the Harvard Medical School Excellence in Tutoring Award. He is also the recipient of the Distinguished Clinician Award from Brigham and Women’s Hospital.

Dr. Biederman is Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD at the Massachusetts General Hospital, Director of the Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorders at the Massachusetts General Hospital, and Professor of Psychiatry at the Harvard Medical School. Dr. Biederman is Board Certified in General and Child Psychiatry.
Dr. Biederman has been a mentor to more than 15 junior investigators in the field. He is on the editorial board of multiple journals, a reviewer for many Psychiatric journals, and has served as a grant reviewer in the Child Psychopathology and Treatment Review Committee of the NIMH. Dr. Biederman is the author and co-author over 800 scientific articles, 650 scientific abstracts, and 70 book chapters.
In October 2007, Dr. Biederman was ranked as the second highest producer of high-impact papers in psychiatry overall throughout the world by the Institute for Scientific Information (ISI). The same organization ranked Dr. Biederman at #1 in terms of total citations to his papers published on ADD/ADHD in the past decade. In 2014, Thompson Reuters named Dr. Biederman on their list of The World’s Most Influential Scientific Minds, as ranking in the top 1% by citations for the field of psychiatry. Dr. Biederman’s work is supported by multiple federal and pharmaceutical industry grants.

Dr. Timothy Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School.
Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent and adult psychiatry at Mass General.
Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models, and the pharmacotherapy of ADHD across the lifespan. He has published more than 300 peer-reviewed articles, concerning these and related topics. He has also coedited more than 80 book chapters, 4 books, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and is on the editorial boards or is a scientific reviewer for more than 35 journals.

Dr. Kelly is the Elizabeth R. Spallin Professor of Psychiatry in the Field of Addiction Medicine at Harvard Medical School – the first endowed professor in addiction medicine at Harvard. He is the Founder and Director of the Recovery Research Institute (RRI) at Massachusetts General Hospital (MGH), the Program Director of the Addiction Recovery Management Service (ARMS), and the Associate Director of the Center for Addiction Medicine (CAM) at MGH.
Dr. Kelly is a past President of the American Psychological Association (APA) Society of Addiction Psychology, is a Fellow of the APA, and a Diplomate of the American Board of Professional Psychology (ABPP). He has served as a consultant to U.S. federal agencies such as the White House Office of National Drug Control Policy (ONDCP), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institutes of Health (NIH); to national non-federal treatment institutions, such as the Hazelden Betty Ford Foundation and Caron Foundation; and to foreign governments. His clinical and research work has focused on the addiction treatment and recovery process, which includes research on the translation and implementation of evidence-based practices, reducing stigma associated with addiction, addiction and criminal justice, and addiction treatment theories and mechanisms of behavior change.
Dr. Kelly has been awarded a Patient’s Choice Winner by Opencare as Best of 2016 – Psychologists in Boston, MA

Dr. Kehoe is the medical director of the Massachusetts General Hospital Substance Use Disorder Bridge Clinic, an immediate access, low barrier transitional clinic, which is a component of MGH’s Substance Use Disorder Initiative. She is an Assistant Professor of Medicine at Harvard Medical School and she received her A.B. from Washington University in St. Louis, her MD from Tufts University School of Medicine, and her MPH from Boston University School of Public Health. She completed her residency in internal medicine at Massachusetts General Hospital, and is board certified in both internal medicine and addiction medicine. She has cared for patients in primary care, inpatient, residential and outpatient addiction treatment settings, and as a medical director at a Boston area methadone maintenance treatment program.
Dr. Kehoe was the co-chair of the hospital-wide Substance Use Disorder Education Committee, and led the trainings for the MGH “Get Waivered” program which resulted in >90% of all Emergency Department physicians waivered to prescribe buprenorphine (suboxone). She teaches locally, regionally and nationally about addiction where she has led workshops and delivered invited symposia at national conferences and continuing education courses. She is the co-chair of the American Society of Addiction Medicine (ASAM) Prisoner Health Interest Group, and a member of the ASAM Annual Conference Planning Committee.
Dr Kehoe mentors providers and health care teams to incorporate addiction treatment into general medical settings, and was a panelist clinical innovator at the Boston “HUBweek: Deep Dive into the Opioid Epidemic,” featured in Harvard Medical School/National Institute of Drug Abuse (NIDA) joint on line education course “Understanding Addiction,” and NOVA’s PBS documentary “Addiction.”

Dr. Sabine Wilhelm is the Chief of Psychology and the Director of the Obsessive-Compulsive and Related Disorders Program at Massachusetts General Hospital. She is a Professor of Psychology (Psychiatry) at Harvard Medical School.
Dr. Wilhelm is recognized as a leading researcher in obsessive-compulsive and related disorders, and has published over 270 articles and reviews on cognitive functioning, prevalence and treatment outcomes of these disorders. She is especially interested in the development and testing of new technologies to treat illness and improve quality of life. Dr. Wilhelm has published seven books on OCD and related disorders. She is the Vice-Chair of the Scientific Advisory Board of the International OCD Foundation, and she serves on the Scientific Council for the Anxiety and Depression Association of America as well as on the Tourette Syndrome Association Behavioral Science Consortium.
Dr. Wilhelm is past president for the Association for Behavioral and Cognitive Therapies (ABCT). Dr. Wilhelm currently serves on eight editorial boards. Additionally, Dr. Wilhelm is a fellow of the Association for Psychological Science. In 2018 Dr. Wilhelm received the Peter K. Ranney Innovation Award from the World Medical Innovation Forum at Partners HealthCare for her presentation “Bridging the Mental Health Treatment Gap.” In addition, she was awarded the Aaron T. Beck Award presented by the Academy of Cognitive Therapy in 2018. Dr. Wilhelm has been the principal investigator or site principal investigator of seven NIMH-funded research grants. She is also the principal investigator of several privately-funded clinical research studies investigating medication, cognitive-behavioral therapy, digital services, and other treatments for OCD and related disorders in children and adults.

Dr. Aude Henin is co-Founder and co-Director of the Child Cognitive Behavior Therapy Program in the Department of Psychiatry at Massachusetts General Hospital, and an Assistant Professor of Psychology at Harvard Medical School. She specializes in the cognitive-behavioral treatment of children and adolescents with mood, disruptive behavior, and anxiety disorders. Her research focuses on the efficacy of cognitive behavioral interventions for children, adolescents, and young adults with anxiety disorders and bipolar disorder as well as longitudinal studies of children at risk for mood and anxiety disorders.

Dr. Sprich is the Director of the Cognitive-Behavioral Therapy Program at Massachusetts General Hospital (MGH). She is also the Director of Postgraduate Psychology Education at the Psychiatry Academy at MGH. She received her doctorate in clinical psychology from the State University of New York at Albany. She is an Assistant Professor in Psychology at Harvard Medical School. Her primary research interests are cognitive-behavioral treatment of ADHD in adults and adolescents, and cognitive-behavioral treatment of OC-Spectrum disorders in children, adolescents in adults. Clinically, she treats individuals with anxiety, ADHD, mood and OC-Spectrum disorders. She also teaches seminars and does supervision with the interns and residents at MGH.

Andrew A. Nierenberg, MD holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Massachusetts General Hospital (MGH) and is the Director of the Dauten Family Center for Bipolar Treatment Innovation, Associate Director of the Depression Clinical and Research Program, and Director of Center for Clinical Research Education, Division of Clinical Research, MGH Research Institute. Dr. Nierenberg’s academic appointment is Professor of Psychiatry at Harvard Medical School. He has published over 470 papers and has been listed among the Best Doctors in North America for the treatment of mood and anxiety disorders continuously since 1994. He has received the National Depression and Manic Depression Association (NDMDA), Depression and Bipolar Support Alliance Gerald L. Klerman Young Investigator and Senior Investigator Awards and the MGH Psychiatry Mentorship Award. Additionally, Dr. Nierenberg has been awarded the Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research, and was listed among the World’s Most Influential Scientific Minds in 2014, 2015, 2016, and 2017 by Clarivate for being in the top 1% of literature citations in psychiatry or psychology worldwide. In his spare time, Dr. Nierenberg is an avid cyclist and a struggling tenor and soprano saxophone player.

Dr. Freudenreich works as an attending psychiatrist and resident supervisor in the the MGH Psychosis Clinical and Research Program. His academic interest is in the area of optimal psychopharmacological treatment for schizophrenia, including clozapine for refractory psychosis, early course schizophrenia, the role of medical morbidity in schizophrenia, the integration of medicine and psychiatry, and treatment adherence. In addition to his clinical and clinical trial expertise in schizophrenia, Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness or diagnostically difficult cases with psychosis. He is a deputy editor for the journal Psychosomatics. He has published extensively in his areas of interest and he wrote a handbook on psychotic disorders. Dr. Freudenreich is an active teacher who lectures regularly at national meetings and at his home institution. At MGH, he is the course director for the Department of Psychiatry’s monthly Morbidity and Mortality conference.
Dr. Freudenreich received his medical degree from the University of Heidelberg in Germany. He completed his psychiatric residency at UMDNJ/Rutgers in New Jersey. Additional training included a 2-year fellowship at Duke University in psychiatric research and a 1-year fellowship at MGH in psychosomatic medicine. The Duke fellowship exposed him to clinical trials methodology as well as sophisticated psychopharmacology of schizophrenia. For his involvement in research and medical education, he has received fellowships from the Society of Biological Psychiatry, from the Academy of Psychosomatic Medicine, and the American Association of Directors of Psychiatric Residency Training.

Marlene P. Freeman, M.D. is a Professor of Psychiatry, Harvard Medical School and the Abra Prentice Foundation Chair in Women’s Mental Health at Massachusetts General Hospital. She is the Associate Director of the Center for Women’s Mental Health at Massachusetts General Hospital and the Medical Director of the MGH Clinical Trials Network and Institute (CTNI).

Dr. Cohen is Director of The Ammon-Pinizzotto Center for Women’s Mental Health at Massachusetts General Hospital. He is a national and international leader in the field of women’s mental health and was among the founders of the field of Perinatal and Reproductive Psychiatry.  His work spans the domains of research, teaching and clinical care in the area of treatment of mood and anxiety disorders with subspecialty interest in psychiatric disorders associated with female reproductive function.

Dr. Uma Naidoo is a board-certified, Harvard-trained psychiatrist who also trained as a Professional Chef, and studied Nutrition. Upon graduating from the Cambridge School of Culinary Arts, she won the school’s most coveted award, the MFK Fisher Award for Innovation in Cooking. She is the author of the first book in Nutritional Psychiatry called: “This Is Your Brain on Food,” which is based on her clinic and her research.

Dr. Naidoo is the Founder and Director of Nutritional and Lifestyle Psychiatry at Massachusetts General Hospital (MGH), the first and only such hospital-based program in the United States. At MGH, Dr. Naidoo also serves as the Director of Nutritional Psychiatry at the MGH Academy, the world-renowned educational organization, for which she designed and released the only CME-based Nutritional Psychiatry educational program for clinicians.

In addition to her work at MGH, Dr. Naidoo serves on the faculty at Harvard Medical School where she worked to integrate Nutritional Psychiatry into the MGH/McLean residency training curriculum since 2016. She is on the faculty of the Harvard Department of Nutrition; and The Cambridge School of Culinary Arts. Dr. Naidoo was commissioned by the American Psychiatric Association to write the first textbook in Nutritional Psychiatry.

She serves as a regular media contributor at CNBC and is on the Harvard Health Publishing Editorial Advisory Board. She has been invited by the World Economic Forum to consult on their New Frontiers of Nutrition initiative.

Internationally after being one of only four US physicians to be invited to meet personally with the former HRH The Prince of Wales, now King Charles III, she was asked to lead a public health Food for Mood Campaign with the UK College of Medicine, where she serves as the US Ambassador for Mental Health.

Stemming from her Hindu roots which emphasize the mind-body connection, Dr. Naidoo has spent her life exploring the connection between mood and food. In her work, she aims to offer individuals more tools to improve their mental well-being using nutrition, lifestyle and metabolic health as the basis of her clinical work and research.